May '25 was a big month for Neurotech. Let's talk about it.

If you’ve been watching the neurotechnology space for a while, May 2025 might’ve felt like the moment the field finally tipped. The research is still rigorous, the challenges are still real - but the headlines no longer read like a science fiction tease. This past month, we witnessed the first real signals of commercial integration, direct patient impact, and meaningful regulatory traction.

In other words: it’s no longer a question of if neurotech will shape our lives, but how soon - and how deeply.

The big idea I want to argue this month is simple: when companies like Apple begin building native brain-computer interface (BCI) support into their core platforms, it’s no longer an experiment - it’s a shift in infrastructure. May didn’t just mark progress. It marked legitimacy. And not just from scrappy startups or research institutions, but from trillion-dollar companies, federal health regulators, and global policy frameworks.

Let’s unpack what happened - and why it matters, especially for those who’ve never given BCI a second thought.

One of the most consequential developments this month came, unsurprisingly, from Cupertino. Apple announced native integration between iOS and Synchron’s brain-computer interface, enabling people with severe motor impairments to control iPhones and iPads using thought alone.

It wasn’t announced at a flashy keynote. There was no “one more thing.” It came as an accessibility update - quiet, pragmatic, and thoroughly Apple.

The device in question, Synchron’s Stentrode, is implanted via the jugular vein and sits within blood vessels near the motor cortex - avoiding open-brain surgery altogether. The real news this month, however, was Apple’s decision to support it as a native input device within iOS, through a new Human Interface Device (HID) protocol that translates neural signals into cursor control, keyboard actions, and more [1].

Apple only invests in this level of OS-level integration when it sees long-term, scalable value. Think AirPods, Face ID, or screen readers: they all began as assistive technologies, then went mainstream. If BCI follows the same trajectory, we’re looking at the early infrastructure of neural input for the general public - not just for patients.

Neuralink, often more known for its press buzz than peer-reviewed papers, made real regulatory progress this month. The company was granted Breakthrough Device designation by the FDA for its speech-restoration BCI designed for individuals with paralysis [2].

This doesn’t mean full market approval yet - but it dramatically speeds up review timelines and prioritizes the device within FDA pipelines. It’s the clearest signal yet that regulators see genuine therapeutic potential in Neuralink’s work.

The device, implanted in the motor cortex, translates intended speech into real-time text or voice output. While Neuralink has flirted with “telepathy” in past marketing language, this month’s focus was grounded and human: enabling locked-in patients to communicate again. That makes a big difference - not only in regulatory posture, but in public trust.

Meanwhile, a quieter but no less astonishing milestone came from ONWARD Medical, a medtech company focused on spinal cord injury. In May, the company performed its fourth and fifth human implant of the ARC-BCI system - a brain-spine interface that restores voluntary movement in paralyzed individuals [3].

The system detects motor intention via a brain implant and wirelessly transmits those signals to a stimulator embedded in the spinal cord. Unlike earlier BCIs designed to control external devices, this one aims to reactivate the body itself.

Early recipients have demonstrated the ability to intentionally walk and climb stairs - sometimes after years of complete immobility. This is no longer assistive tech - it’s restorative. It’s the brain taking back control of the body.

Historically, if you weren’t part of a clinical trial or working at a cutting-edge research institution, building with BCI tech was essentially impossible. That changed in May.

Cognixion and Blackrock Neurotech announced the release of the Axon-R headset: a wireless, AR-enabled, EEG-based BCI device specifically designed for developers [4].

It’s a major step. This device isn’t implanted - it’s wearable. It reads cognitive signals like attention, intent, and emotional state. Crucially, it comes with a robust SDK that allows developers to start building neuroadaptive applications immediately.

Think of it as the MacBook Pro of neural interfaces - not yet mass-market, but powerful enough to seed an entire generation of innovation.

The tech wasn’t the only thing that advanced this month. So did the rules.

UNESCO released preliminary guidance on international neurotech ethics, with an emphasis on informed consent, cognitive liberty, and data sovereignty [5]. The European Commission published a detailed foresight report urging immediate action on neural data governance [6]. And in the U.S., members of Congress formally requested that the FTC treat neural data as a protected class under digital privacy laws [7].

Why does this matter?

Because neural data is uniquely personal. Unlike browser history or location data, you can’t reset your neural signature. You can’t log out of your brain. Without legal protections, the potential for misuse is enormous - from predictive hiring algorithms to surveillance-based insurance pricing.

The work is early - but it’s finally happening, and it’s finally coordinated. That’s new.

This wasn’t just a strong month for neurotech. It was a stack-level signal: from implants to wearables, from patient care to developer access, from individual use to global policy, every layer of the ecosystem moved forward.

Most tellingly, Apple didn’t just approve a neural interface - it designed for it. That’s a watershed moment. Once a company of that scale updates its operating system to accommodate brain input, the rest of the industry can’t afford to ignore it. Not app developers. Not device makers. Not regulators. Not investors.

That’s how paradigm shifts happen.

From “I’d never put a chip in my brain,” to “my mom just uses hers to text.”

From clinical trial to consumer interface.

If you’re not paying attention to neurotech yet, May 2025 should change that.

Whether you’re a technologist, policymaker, investor, or designer - or simply someone who cares about the future of human experience - this is no longer a curiosity. It’s a channel. A new kind of interface.

The question is no longer if your brain will interact with machines.It’s when, how, and on whose terms.

I’ll be here each week to help you navigate that future - thoughtfully.

Until next time,—Daniel Kim

[1] Apple & Synchron integration coverage: Business Wire, May 13, 2025 [2] Neuralink FDA Breakthrough Device announcement: Reuters, May 1, 2025[3] ONWARD Medical fourth and fifth ARC-BCI implant: Bio Space, May 21, 2025[4] Cognixion & Blackrock Axon-R launch: Cognixion, May 14, 2025[5] UNESCO Neuroethics Guidelines (Draft): unesco.org, May 7, 2025[6] EU Foresight Report on Neural Data: EU Policy Lab, May 26, 2025[7] U.S. Congressional Letter to FTC on Neural Data Privacy: The Washington Post, April 28, 2025